Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AZNCF crawled time : 14:20 save search
Global 3D Printed Drugs Market Report to 2027: Benefits Associated with 3D Printed Drugs Fuel the Sector
Published: 2023-04-03 (Crawled : 14:20) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: -1.77%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: -2.41%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.11%
H: 0.95%
C: 0.93%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.17%
H: 0.6%
C: 0.55%
report global benefits market
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | News | $1.3004 1.87% 15K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: -1.6%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: -4.6%
ATXI | $0.1301 1.66% 280K
|
Health Technology
|
| O: 7.78%
H: 6.67%
C: -7.78%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.2%
H: 0.96%
C: 0.18%
treatment acquisition system therapeutics positive
Advanced Parenteral Drug Delivery Devices Market to hit US$ 4.99 Billion by 2030 | Exclusive Report by Growth Plus Reports
Published: 2022-10-06 (Crawled : 14:20) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -2.53%
H: 0.0%
C: 0.0%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -1.91%
H: 1.22%
C: -0.8%
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -1.42%
H: 0.38%
C: -0.3%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: -1.25%
H: 0.53%
C: -0.1%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.92%
H: 0.06%
C: -0.78%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: -0.5%
H: 0.34%
C: -0.4%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -2.45%
H: 0.54%
C: -0.78%
drug report plus growth market
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
Published: 2022-05-27 (Crawled : 14:20) - biospace.com/
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: -2.27%
H: 2.43%
C: -0.25%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.15%
H: 0.9%
C: 0.9%
lupus trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.